![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » XELODA FILED IN EUROPE FOR TREATMENT OF ADVANCED STOMACH CANCER
XELODA FILED IN EUROPE FOR TREATMENT OF ADVANCED STOMACH CANCER
July 21, 2006
The European Medicines Agency informed Roche that the filing for a new indication in Europe for the oral cancer drug Xeloda (capecitabine) in combination with another chemotherapy (cisplatin) for the treatment of patients with advanced gastric (stomach) cancer has been accepted. Stomach cancer is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Roche (http://www.roche.com/med-cor-2006-07-21)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct